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Abstract Patients with glutaric aciduria type 1 (GA1), a
rare inherited metabolic disorder, have an increased risk
for subdural hematomas (SDHs). GA1 is therefore gen-
erally included in the differential diagnosis of children
presenting with SDHs. This retrospective cohort study
reviews all 25 registered, in the Dutch Diagnosis
Registration for Metabolic Disorders, GA1 patients in
the Netherlands. This was done between May 2014
and November 2014 to determine the lifetime incidence
of SDHs in this population. Seventeen patients were
diagnosed either due to clinical symptoms or because
of family members with GA1. One out of these 17
had a SDH. This patient showed widened Sylvian fis-
sures on MRI, characteristic for GA1. Eight patients
were diagnosed by newborn screening. Three of them
had neuroimaging results, and none of them had
SDHs. This study shows an overall lower incidence
(4.0 %) of SDHs in patients with GA1 than reported
in the literature (20–30 %).
Conclusion: This finding, in combination with the
fact that SDHs in GA1 appear to occur only in the
presence of characteristic brain abnormalities on imag-
ing, we recommend that GA1 should not routinely be a
part of the differential diagnosis of children with unex-
plained SDHs in the absence of imaging characteristics
suggestive of GA1.
What is known:
• Glutaric aciduria type 1 is a rare metabolic disorder predisposing
children to subdural hematoma development due to brain
abnormalities.
• Because of these subdural hematomas, glutaric aciduria type 1 testing is
part of abusive head trauma work-up.
What is new:
• The overall subdural hematoma incidence in glutaric aciduria type 1
patients is much lower than previously reported and only occurs in case
of predisposing brain abnormalities.
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Introduction
Glutaric aciduria type 1 (GA1, OMIM#231670) is a rare,
autosomal recessive inborn error of metabolism caused by
a deficiency of glutaryl-CoA dehydrogenase (GCDH).
This enzyme is involved in the breakdown of the amino
acids lysine, hydroxylysine and tryptophan [13].
Deficiency of GCDH can result in the accumulation of
intermediate breakdown products, particularly of glutaric
acid and 3-hydroxy-glutaric acid which are neurotoxic
[16]. The prevalence of GA1 is estimated to be 1 in
100,000 live newborns [18]. The main clinical presenta-
tion consists of macrocephaly and encephalopatic crisis,
often triggered by a minor infection within the first
36 months of life. As a consequence of an encephalopatic
crisis, other symptoms develop including orofacial dyski-
nesia, choreoathetosis, epilepsy, dystonia, and cognitive
impairment [15]. Although up to 25 % of untreated pa-
tients remain completely asymptomatic, GA1 is associated
with high morbidity and mortality [6]. Treatment consists
of a low lysine diet with supplementation of essential
amino acids and carnitine which may prevent the devel-
opment of neurological damage in asymptomatic patients
[14, 15]. Because of the importance of an early start of
treatment, aiming at prevention of irreversible central ner-
vous system (CNS) damage, GA1 is included in the new-
born screening (NBS) panel in many countries [13], in-
cluding the Netherlands where it was introduced in 2007.
Neuroradiological imaging may reveal several abnormali-
ties in GA1 patients. The most characteristic anomaly is the
Bbatwing sign^ due to reduced operculization of the brain,
also referred to as widening of the Sylvian fissures, which is
reported in up to 93 % of patients [24, 26]. This can be ac-
companied by bilateral frontotemporal cortical atrophy and
enlargement of ventricular spaces and mesencephalic cisterns
caused by a delayed start of treatment or due to acute enceph-
alopathic crises [1, 24]. In addition, subdural hematomas
(SDHs) have been reported as complications in GA1 patients.
Although brain abnormalities are generally detected on brain
imaging performed during or after a metabolic crises, studies
in patients detected by NBS show that extensive radiological
changes may already be present very early in life in the ab-
sence of clinical disease [14, 23], demonstrating that at least
part of the morphological changes originate during intra-
uterine life [9]. Furthermore, in utero MRI studies have
established a maturational delay of the brain leading to hypo-
plasia and immature gyral patterns [5]. These in utero abnor-
malities can normalize later on however [17, 19].
Usually SDHs in children with GA1 occur in cases
with preexisting neuroimaging abnormalities [25]. The
cortical atrophy and expanded cerebrospinal fluid (CSF)
spaces may cause stretching of the cortical veins, which
may cause them to rupture [9]. This mechanism explains
why GA1 patients are considered to be more vulnerable to
the development of subdural hematomas after minor trau-
ma compared to healthy children. Conversely, cerebrovas-
cular changes like arteriolar dilation and increased cere-
bral blood volume could be the cause of CSF expansion
and SDHs by creating venous hypertension [22]. The in-
cidence of SDHs in GA1 children has been estimated at
20–30 % outside the Netherlands [20]. In pediatric litera-
ture, GA1 is a routine part of the work-up of SDH in case
of suspected abusive head trauma (AHT) [13].
Patients with SDHs associated with undiagnosed GA1
have been erroneously diagnosed as AHT [6], and as a
consequence, urine, blood, and/or enzymatic GA1 inves-
tigations to exclude this disorder are advised in case of
SDH in suspected AHT. However, a priori chance of an
unknown case of GA1 when dealing with a SDH with an
otherwise normal brain is very low, especially since the
introduction of GA1 in NBS programs. The aim of this
study therefore is to investigate the prevalence of SDHs in
a Dutch cohort of patients with GA1 and to assess the
related neuroimaging results.
Materials and methods
A retrospective review of all Dutch GA1 patients was per-
formed between May 2014 and November 2014. Dutch
GA1 patients are registered in the Dutch Diagnosis
Registration for Metabolic Disorders, founded in 2001 [2].
This is a collaborative database of the seven metabolic centers
in the Netherlands and formed the basis of our study. In four of
these centers, i.e., the Academic Medical Center Amsterdam,
the Erasmus Medical Center in Rotterdam, the University
Medical Center Groningen, and the University Medical
Center Utrecht, patients with GA1 were seen for follow-up.
All patients with confirmed laboratory GA1 diagnosis at the
time of review were included, no exclusion criteria were used.
Patient records were screened by one researcher (MV) for
patient demographics and clinical history. Neuroimaging results
were evaluated, and in cases of the presence of a SDH, the
radiological imaging was reevaluated by a forensic pediatric
radiologist (RvR).
All extracted data were handled anonymously. The inter-
nal review board of the Academic Medical Center
Amsterdam has issued a waiver for retrospective anonymized
patient medical record studies, specific approval for this
study therefore was not mandatory.
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Results
Twenty-five patients with GA1 were identified, 17 males and
8 females. All but one were alive at the time of the study
(Table 1). Four patients (16.7 %) had GA1 relatives who were
also included in this study. Patients 1 and 5 are brothers, as are
patients 3 and 4. Patients were divided into two groups. The
first group of patients, who were diagnosed before NBS for
GA1 was introduced, consisted of 17 patients (70.8 %) with a
median age at time of diagnosis of 2.5 years (range 0 months–
8 years). The second group with eight patients was identified
by NBS. All patients received appropriate therapy from the
time of diagnosis (Table 2).
According to the Central Bureau of Statistics (CBS) of the
Netherlands, there were approximately 6,310,000 children
born between 1980 and 2014 and a 99.8 % compliance with
the NBS program. Therefore, the incidence of GA1 in the
Netherlands is approximately 1 in 200,000 persons.
Clinical diagnosis group
The clinically diagnosed group had a median age of 17.9 years
(range 10–33 years) at the time of this study. The head cir-
cumference defined in standard deviations (SD) was on aver-
age +1.04 SD (range −2 SD to >3 SD). Neuroimaging studies
were available in 15 patients of whom 12 had one or more
MRI scans (range 1–3), 6 had one or more CTscans (range 1–
3), and 3 patients had undergone both MRI and CT. In this
latter group, 1 child (Table 1, case 14) was diagnosed with a
SDH (Fig. 1).
Newborn screening group
None of the patients in the NBS group had family members
previously diagnosed with GA1. The median age of these
patients at time of this study was 4.0 years (range
11 months–7 years). With a median head circumference of
+0.69 SD (range −1 SD to +2.5 SD), the NBS patients had a
similar deviation to the patients in the clinical diagnosis group.
Five patients did not have CTorMRI scans, 2 patients had one
or more MRI scans (range 1–2) and 1 had a CT scan once.
There were no cases of SDH in this group.
Discussion
Our study demonstrated a rather low incidence (5.9 %) of SDH,
in GA1 patients identified before the use of NBS, compared to
the reported incidence of SDHwhich ranges from 10 to 30 % in
children with GA1 in most literature reports [4, 8]. There is
however one large retrospective study with a SDH incidence Ta
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of 0 % on MRI [5]. The lower overall birth incidence in the
Dutch population compared to previously internationally report-
ed incidences needs to be taken into account. Because of a
national-based database, we are quite confident we did not miss
any cases. This low incidence might be due to prenatal counsel-
ing. Furthermore, none of the 3 patients who were diagnosed
with GA1 through NBS and of whom imaging results were
available had a SDH. The overall incidence in our study popu-
lation is 4.0 %. The aim of early diagnosis by NBS is to start
treatment as early as possible. Even though up to 25 % of un-
treated patients remained completely asymptomatic, the aim of
the treatment is to reduce the risk of CNS complications, includ-
ing the risk of SDH development [13]. The only patient in our
cohort in whom SDH was diagnosed was born before the intro-
duction of GA1 in NBS in the Netherlands. SDHs are thus less
frequently seen in GA1 children than has been reported by
some. Nevertheless, these children are still at risk of significant
hemorrhage, even if diagnosed by NBS and treated according to
recent guideline recommendations.
Although all Dutch GA1 patients were included, the rela-
tive small amount of patients remains a limitation. Another
limitation of this study is that 2 out of 17 of the clinical pa-
tients and 5 out of 8 of the NBS group patients did not have
any neuroimaging results. However, these patients did not
have any clinical signs of a SDH, such as a change in head
circumference, an altered level of consciousness, vomiting,
paralysis, seizures, or other relevant neurological symptoms,
during their out-patient clinic follow-up, thus obviating the
need of neuroimaging. We therefore feel confident that no
cases of SDH were missed.
Fig. 1 T2-weighted MRI of a boy at 6 months old (patient no. 14) with
subdural collections. MRI settings: T2 SE, slice thickness 6 mm, TR:
3465, TE 150, flip angle 90°, NSA: 1. Clinical history revealed a
consistent macrocephaly and mild retardation, no signs of acute
neurological deterioration. MRI shows symmetrical fronto-parieto-
occipital subdural collections (asterisk), atrophy of the frontal lobes,
and bilateral wide Sylvian fissures (arrows). The imaging findings are
consistent with GA1. The work-up for child abuse revealed no concern
1004 Eur J Pediatr (2016) 175:1001–1006
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Themost common cause of SDHs is AHT [11], other causes
include birth trauma, accidental trauma,meningitis, coagulation
disorders, and metabolic disorders including GA1 [7]. In the
past, SDH cases due to GA1 have been misdiagnosed as AHT
[12]. GA1, although a rare cause of SDHs, is generally included
in the forensic-medical differential diagnosis of SDH due to
suspected AHT [13], which has serious social and medico-
legal consequences [6]. Unnecessary delay in AHT diagnosis,
for instance by GA1 testing, is thus avoidable. The outcome of
AHTwith SDHs is poor, with a mortality of 15–23 % [3, 7, 11,
21]. Surviving children have a high morbidity rate of 64 % of
which half is severe [3]. Abuse should thus at least be consid-
ered and investigated. It is important to keep in mind that a
diagnosis of GA1 does not rule out the possibility of AHT,
since both conditions can coexist [8, 26]. In addition, disabled
and chronically ill children are even more prone to become
victims of abuse [8, 10].
This study shows an overall low incidence of SDHs in
patients with glutaric aciduria type 1 in our Dutch population.
The incidence might become even lower in the future due to
early treatment after positive NBS. This combined with the
high NBS compliance of 99.8 % and the fact that SDHs in
GA1 appear to occur usually in the presence of characteristic
brain abnormalities on imaging, we recommend that GA1
should not routinely be a part of the differential diagnosis of
children with unexplained SDHs in the absence of imaging
characteristics suggestive of GA1.
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